Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells

Manuelle Viguier, Fabrice Lemaître, Olivier Verola, Min-Sun Cho, Guy Gorochov, Louis Dubertret, Hervé Bachelez, Philippe Kourilsky and Laurent Ferradini

*J Immunol* 2004; 173:1444-1453; doi: 10.4049/jimmunol.173.2.1444
http://www.jimmunol.org/content/173/2/1444

**References**
This article cites 64 articles, 37 of which you can access for free at:
http://www.jimmunol.org/content/173/2/1444.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Foxp3 Expressing CD4⁺CD25⁺high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells

Manuelle Viguier,²* Fabrice Lemaître,* Olivier Verola,† Min-Sun Cho,* Guy Gorochov,* Louis Dubertret,† Hervé Bachelez,† Philippe Kourilsky,* and Laurent Ferradini²*

Dominant tolerance is mediated by regulatory T cells (Treg) that control harmful autoimmune T cells in the periphery. In this study, we investigate the implication of Treg in modulating infiltrating T lymphocytes in human metastatic melanoma. We found that CD4⁺CD25⁺high T cells are overrepresented in metastatic lymph nodes (LNs) with a 2-fold increased frequency compared with both tumor-free LNs and autologous PBMCs. These cells express the Foxp3 transcription factor, display an activated phenotype, and display a polyclonal TCR Vβ chain repertoire. They inhibit in vitro the proliferation and cytokine production of infiltrating CD4⁺CD25⁻ and CD8⁺ T cells (IL-2, IFN-γ) through a cell-contact-dependent mechanism, thus behaving as Treg. In some cases, the presence of Treg type 1/Th3-like lymphocytes could also be demonstrated. Thus, Treg are a major component of the immunosuppressive microenvironment of metastatic melanoma LNs. This could explain the poor clinical response of cancer patients under immunotherapeutic protocols, and provides a new basis for future immunotherapeutic strategies counteracting in vivo Treg to reinforce local antitumor immune responses. The Journal of Immunology, 2004, 173: 1444–1453.

Melanoma is considered as an important immunogenic tumor model because of the well-known occurrence of spontaneous regressions (1), the identification of numerous tumor-associated Ags (2), as well as the detection of Ag-experienced antitumor-specific T cells in vivo (3). Attempts to induce specific antitumoral T cell responses through various immunotherapeutic protocols have revealed the potential of vaccination in inducing in some cases regression of large tumor burden. However, such favorable outcomes are still limited and await further analysis of correlations between antitumor T cell responses and clinical improvement (4–9). The reasons behind the limited success of these approaches are still largely unknown. It is possible that the induced T cell responses are not the most appropriate in terms of quantity, differentiation, or capacity to home tumor sites. In contrast, the tumor itself may have developed immune escape strategies, including impairment of Ag presentation or secretion of immunosuppressive molecules like IL-10 or TGF-β (10). However, the in vivo nature of such a T cell counteractive microenvironment remains largely unknown.

Received for publication March 3, 2004. Accepted for publication May 6, 2004.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work is funded by the Ligue Contre le Cancer (Comité de Paris), Association pour la Recherche Contre le Cancer, INSERM, and the Institut Pasteur (Paris, France). M.V. was supported by a poste d’accueil INSERM and M-S.C. by a poste vert INSERM.

2 Address correspondence and reprint requests to Dr. Manuelle Viguier or to Dr. Laurent Ferradini, INSERM U277, Unité de Biologie Moléculaire du Gène, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France. E-mail address: mviguier@pasteur.fr or lferradini@epicentre.msf.org

³ Abbreviations used in this paper: Treg, regulatory T cells; Tr1, Treg type 1; LN, lymph node; GITR, glucocorticoid-induced TNFR; HPRT, human hypoxanthine ribosyltransferase 1; MFI, mean fluorescence intensity; CD3, complementarity-determining regions 3; int, intermediate; TCRVβ, TCR Vβ.

Copyright © 2004 by The American Association of Immunologists, Inc. 0022-1767/04/S02.00
responses, which could explain the poor clinical response of cancer patients under immunotherapeutic protocols, remains to be demonstrated.

In the present study, we investigated the idea that \( T_{reg} \) could be involved in the control of the local immune response in human metastatic melanoma. We found that the frequency of CD4\(^+\)CD25\(^{high}\) T cells is clearly increased in metastatic lymph nodes (LN)s compared with tumor-free satellite LN and autologous PBMCs. These tumor-infiltrating CD4\(^+\)CD25\(^{high}\) T cells express the Foxp3 transcription factor, display a phenotype of activated memory T cells, and inhibit in vitro the proliferation and cytokine production of autologous infiltrating CD4\(^+\)CD25\(^{low}\) as well as CD8\(^+\) T cells in a cell-contact-dependent manner. Thus, our data provide the first evidence that CD4\(^+\)CD25\(^{high}\) T cells infiltrating human metastatic melanoma LN behave as previously described CD4\(^+\)CD25\(^{high}\) T cells. In addition, we found that distinct subsets of \( T_{reg} \) may also operate locally.

Materials and Methods

Patients and samples

Twelve patients undergoing curative resections for LN metastatic melanoma, after any immunotherapy or chemotherapy were included in this study after informed consent following human ethics committee procedures (Comité Consultatif pour la Protection des Personnes dans les Recherches Biomédicales; Hôpital Saint-Louis, Paris, France). Cancer stage was gathered according to the American Joint Committee on Cancer (AJCC). LN cell suspensions, obtained after sterile mechanical dissociation, were washed, and cryopreserved for further analysis.

Abs and flow cytometric analysis

The following Abs were used: PE-anti-CD25 (M-A521), allophycocyanin anti-CD28 (CD28.2), allophycocyanin anti-CD69 (L78), allophycocyanin anti-CTLA-4 (BN13), allophycocyanin anti-CD45RO (UCHL1), biotinylated anti-cathepsin-lymphocyte-associated Ag (HECA-452), biotinylated anti-CD45RA (HI100), allophycocyanin anti-HLA-DR (Tu21), and anti-CD27 streptavidin (all from BD Pharmingen, San Diego, CA). We also used: FITC anti-CD4 (clone S3.5; Caltag Laboratories, Burlingame, CA) and allophycocyanin anti-CD27 Abs (O323; Bioscience, San Diego, CA). Anti-CCR7 and anti-CXCR5 were kindly provided by Dr. M. Lipp (Max-Debrück-Centrum, Berlin, Germany). For CTLA-4 intracellular staining, the Cytofix/Cytoperm kit was used according to the manufacturer recommendations (BD Pharmingen). Lymphocytes were gated according to their forward and size scatter characteristics, and four-color FACScalibur analysis was performed using the CellQuest software (BD Biosciences, San Jose, CA).

Purification of CD4\(^+\)CD25\(^{high}\), CD4\(^+\)CD25\(^{low}\), and CD8\(^+\) tumor-infiltrating lymphocytes

LN cell suspensions were coated with CD4 and CD8 magnetic microbeads (Miltenyi Biotec, Auburn, CA), together with FITC-anti-CD4 and allophycocyanin anti-CD8 Abs (BD Pharmingen), according to the manufacturer recommendations, and isolated using LS separation columns on VarioMACS (Miltenyi Biotec). The positive fraction was then labeled with PE-anti-CD25 Ab and the T cell populations were purified using a MoFlo Cell Sorter (Dakocytomation, Fort Collins, CO). Purities of CD4\(^+\)CD25\(^{high}\), CD4\(^+\)CD25\(^{low}\), and CD8\(^+\) T cell populations were 92.4 ± 1.3%, 99 ± 1.2%, and 92.6 ± 2.1% (mean ± SD), respectively.

Proliferation assays

A total of 2.5 × 10\(^4\) purified CD4\(^+\)CD25\(^{high}\), CD4\(^+\)CD25\(^{low}\), or CD8\(^+\) T cells were cultured in triplicate with 5 × 10\(^4\) allogeneic irradiated PBMCs in 96-well round-bottom plates in RPMI 1640 medium supplemented with 1 mM L-glutamine, 1% penicillin/streptomycin, nonessential amino acid, sodium pyruvate (all from Invitrogen Life Technologies, Carlsbad, CA), and 10% FCS (Dominique Dutcher, Isy-les-Moulineaux, France). In inhibition assays, infiltrating CD4\(^+\)CD25\(^{high}\) or CD8\(^+\) T cells were cocultured with different numbers of infiltrating autologous CD4\(^+\)CD25\(^{high}\) T cells. \([\text{H}]\)Thymidine (ICN Biomedicals, Irvine, CA) was added at day 5 (1 μCi/well) for 16 additional hours before cell harvesting and counting in a Betaplate scintillation counter (LK Pharma, Uppsala, Sweden). For blocking experiments, CD4\(^+\)CD25\(^{high}\) were preincubated 20 min at 4°C with Abs before being cocultured in 1 μg/ml Ab final concentration. The following blocking Abs were used: anti-CTLA-4 (BNI3; BD Pharmingen), anti-IL-10 (JES5-19F1; BD Pharmingen), anti-TGF-β1,3 (1D11; R&D Systems, Minneapolis, MN), and anti-glucocorticoid-induced TNFR (GITR; clone 110416; R&D Systems), and rat IgG2a, mouse IgG2a,κ, and IgG1,κ immunoglobulins isotype controls (BD Pharmingen). For TCR stimulation, T cells were incubated with soluble anti-CD28 (CD28.2, 1 μg/ml; BD Pharmingen) in 96-well round-bottom plates previously coated overnight at 4°C with anti-CD3 (UCHT1, 0.5–1 μg/ml; Cymbus Biotechnology, Hants, U.K.). For transwell experiments, CD4\(^+\)CD25\(^{low}\) were placed at the bottom of a 96-well round-bottom plate together with irradiated allogeneic PBMCs, and were separated by a 0.2-μm size anopore membrane (Nunc, Roskilde, Denmark) from CD4\(^+\)CD25\(^{high}\) T cells placed together with irradiated allogeneic PBMCs in the top chamber of the transwell. At day 5, the transwell was removed and \([\text{H}]\)thymidine incorporation was measured as described above.

Cytokine production

ELISA was used according to manufacturer recommendations (OptEIA; BD Pharmingen) to detect IL-2, IL-4, IL-10, TGF-β1, and IFN-γ in supernatants of T cell cultures after 5 days of allogeneic stimulation or 3 days of anti-CD3/anti-CD28 stimulation. The minimal levels of detection were 3.9 pg/ml for IL-2, IL-4, and IL-10, 2.3 pg/ml for IFN-γ, and 31.2 pg/ml for TGF-β in four-time diluted supernatants.

Quantitative real-time PCR

RNA were first purified using the RNeasy kit (Qiagen, Carlsbad, CA), and oligo(dT) or random hexanucleotide-primed first strand cDNAs were synthesized using SuperScript II reverse transcriptase (Invitrogen Life Technologies). They were then used as a template for real-time PCR, with the TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA). Specific primers for Foxp3 and human hypoxanthine ribosynthetase 1 (HPRT) were used with the following TaqMan MGB probe (Assays-on-demand gene expression assays; Applied Biosystems): 5′-6FAM-ATCGGCT GGCGCATCTGGAGGCTT-3′ (Foxp3), and 5′-6FAM-GTCTAAGGT CGCAAGCTTCTGGTT (HPRT). Because sequences for the specific unlabelled PCR primers were not provided by the manufacturer, the real-time PCR products for Foxp3 were controlled by sequencing analysis, using an ABI Prism 3700 detection system (Applied Biosystems). Real-time PCR was conducted in a GeneAmp 5700 detection system (Applied Biosystems), with the following cycling conditions: 10 min at 95°C, followed by 40 cycles of 1 s at 95°C, and 1 min at 60°C. The mean values from duplicates were used for calculations. Data are expressed as normalized expression obtained by dividing the relative cDNA level for each sample by the relative cDNA level of HPRT for the same sample, where HPRT = 1.

T cell repertoire diversity

TCR β chain repertoire of sorted infiltrating CD4\(^+\)CD25\(^{high}\) and CD4\(^+\)CD25\(^{low}\) T cells was analyzed by quantitative Immunoscope (Applied Biosystems), as previously described (42, 43). cDNAs obtained after reverse transcription of total RNA with oligos(T)\(_{18}\), and SuperScript II reverse transcriptase (Invitrogen Life Technologies) were amplified with each of 24 TCR βV] subfamily-specific primers and a nested fluorochrome-labeled TaqMan probe for TCR β8. Real-time PCR was conducted in a GeneAmp 5700 detection system (Applied Biosystems). PCR products were used as templates in run-off reactions using a nested TCR β8 fluorescent primer producing labeled ssDNA fragments that were separated on a denaturing 6% acrylamide gel on a 373 DNA sequencer (Applied Biosystems) and analyzed with Immunoscope software (42).

Statistical analysis

Statistical analysis was performed using paired or unpaired Student’s t tests with the Kaleidagraph software (Synergy Software, Reading, PA).
Results

Overrepresentation of CD4⁺CD25high in metastatic melanoma LNs

Because regulatory CD4⁺ T cell activity has been identified in the CD4⁺CD25high T cell subpopulation in human PBMCs and thymocytes (24, 25, 27, 28, 30–33), we first estimated the proportion of such CD4⁺CD25high T cells among lymphocytes infiltrating metastatic LNs in melanoma patients. Our study included 12 patients suffering from stage III melanoma before any treatment other than curative surgical resection (Table I). Isolated lymphocytes were gated to estimate the proportion of CD4⁺ T cells that expressed high level of CD25 (IL-2Rα-chain) and lower level of CD4 as previously described for CD4⁺CD25⁺ Treg (Fig. 1A).

The frequency of CD4⁺CD25high T cells among CD4⁺ T cells was 11.06 ± 1.7% (mean ± SD) in metastatic LNs (range 8.3–14.05%; n = 13). We also studied tumor-free LNs and found that the frequency of CD4⁺CD25high T cells was 6.2 ± 4.2% (n = 16). A global comparison between metastatic LNs and tumor-free LNs revealed almost a 2-fold increased frequency in metastatic LNs (p = 0.0006). The frequency of CD4⁺CD25high T cells in metastatic LNs was also significantly increased when compared with the frequency observed in autologous PBMCs (4.9 ± 1.9%, range 2.6–8.7%, n = 8, p < 0.0001) or in healthy donor PBMCs (5.8 ± 1.7%, range 3–8.2%, n = 10, p < 0.0001). No statistical difference was found between frequencies of CD4⁺CD25high T cells in PBMCs from metastatic melanoma patients and healthy donors (p = 0.37). When performing matched sample analysis (i.e., comparing metastatic LNs with either PBMCs or tumor-free LNs from the same patient), the difference remained highly significant (p = 0.014 and p = 0.016, respectively).

Altogether, these results revealed that the proportion of CD4⁺CD25high T cells is clearly increased in metastatic LNs compared with tumor-free LNs and autologous PBMCs.

Infiltrating CD4⁺CD25high T cells display a memory and activated phenotype

The majority of CD4⁺CD25high T cells in 11 metastatic LNs from 10 patients expressed CD45RO (73.2 ± 11.8%) and were CD45RA positive (18.9 ± 8.5%). They all expressed CD27 and HLA-DR (6.6 ± 2.4%). Thus, most of these CD4⁺CD25high T cells were CCR7 negative (87 ± 6.3%). Indeed, infiltrating CD4⁺CD25high T cells expressed high levels of the activation molecule CD69 (43.8 ± 14.05% vs 15–24%, n = 10, p = 0.0001). No statistical difference was found between frequencies of CD4⁺CD25high T cells in PBMCs from metastatic melanoma patients and healthy donors (p = 0.37). When performing matched sample analysis (i.e., comparing metastatic LNs with either PBMCs or tumor-free LNs from the same patient), the difference remained highly significant (p = 0.014 and p = 0.016, respectively).

Altogether, these results revealed that the proportion of CD4⁺CD25high T cells is clearly increased in metastatic LNs compared with tumor-free LNs and autologous PBMCs.

Infiltrating CD4⁺CD25high T cells express the Foxp3 transcription factor

Foxp3 was recently described as an important transcription factor involved in the development and function of murine CD4⁺CD25⁺ Treg and appears to be the most specific molecular marker available to date (21). We first tested PBMCs from three healthy donors using real-time quantitative PCR. As expected, CD4⁺CD25high T cells expressed high levels of Foxp3 while CD4⁺CD25− T cells expressed only very low levels (Fig. 2, and data not shown). Interestingly, when analyzing Foxp3 expression in nine melanoma metastatic LNs from seven different

Table 1. Characteristics of the melanoma patients studied

<table>
<thead>
<tr>
<th>Patients</th>
<th>Sex</th>
<th>Age (year)</th>
<th>Site of LNs</th>
<th>LNs Dissection</th>
<th>Tumor Stage</th>
<th>Disease Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLM2</td>
<td>M</td>
<td>56</td>
<td>Cervical</td>
<td>1 N³/4 N</td>
<td>IIIb/IIIc</td>
<td>2 year</td>
</tr>
<tr>
<td>SLM6</td>
<td>F</td>
<td>55</td>
<td>Axillary</td>
<td>2 N³/3 N</td>
<td>IIIb/IIIc</td>
<td>Unknown</td>
</tr>
<tr>
<td>SLM8</td>
<td>M</td>
<td>35</td>
<td>Inguino-iliac</td>
<td>1 N³/15 N</td>
<td>IIIb/IIIc</td>
<td>4 year</td>
</tr>
<tr>
<td>SLM11</td>
<td>F</td>
<td>63</td>
<td>Inguino-iliac</td>
<td>4 N³/12 N</td>
<td>IIIc</td>
<td>5 year</td>
</tr>
<tr>
<td>SLM12</td>
<td>M</td>
<td>59</td>
<td>Inguino-iliac</td>
<td>1 N³/8 N</td>
<td>IIIb/IIIc</td>
<td>4 year</td>
</tr>
<tr>
<td>SLM14</td>
<td>M</td>
<td>81</td>
<td>Cervical</td>
<td>1 N³/13 N</td>
<td>IIIc</td>
<td>6 mo</td>
</tr>
<tr>
<td>SLM15</td>
<td>F</td>
<td>64</td>
<td>Inguino-iliac</td>
<td>5 N³/17 N</td>
<td>IIIc</td>
<td>15 mo</td>
</tr>
<tr>
<td>SLM16</td>
<td>M</td>
<td>73</td>
<td>Axillary</td>
<td>2 N³/21 N</td>
<td>IIIb/IIIc</td>
<td>21 mo</td>
</tr>
<tr>
<td>SLM17</td>
<td>M</td>
<td>64</td>
<td>Inguino-iliac</td>
<td>12 N³/24 N</td>
<td>IIIc</td>
<td>6 mo</td>
</tr>
<tr>
<td>SLM18</td>
<td>M</td>
<td>53</td>
<td>Inguino-iliac</td>
<td>3 N³/12 N</td>
<td>IIIc</td>
<td>0</td>
</tr>
<tr>
<td>SLM19</td>
<td>M</td>
<td>23</td>
<td>Axillary</td>
<td>1 N³/11 N</td>
<td>IIIb/IIIc</td>
<td>Unknown</td>
</tr>
<tr>
<td>SLM20</td>
<td>F</td>
<td>55</td>
<td>Inguino-iliac</td>
<td>7 N³/17 N</td>
<td>IIIc</td>
<td>13 year</td>
</tr>
</tbody>
</table>

* Twelve stage III melanoma patients with metastatic LNs were included in this study. The anatomical site of surgical LN resection and the results of histopathological examinations are indicated (N, total LNs resected; N³, metastatic LNs resected). Tumor stages were determined according to the American Joint Committee for Cancer (41). Disease intervals between the removals of the primary cutaneous melanoma and of the metastatic LNs are given. For two patients (SLM6 and SLM19), the primary cutaneous lesion was not evidenced. For another one (SLM18) the primary melanoma and the metastatic LNs were discovered concomitantly.
patients, we found that infiltrating CD4+CD25^{high} T cells highly expressed Foxp3 while CD4+CD25^{-} T cells expressed very low levels (Fig. 2). The levels of Foxp3 expression in CD4+CD25^{high} T cells from metastatic LNs compared with autologous or healthy donor PBMCs were almost similar (Fig. 2). In three tumor-free LNs from different patients, CD4+CD25^{high} T cells also expressed Foxp3 (data not shown). Altogether, these data revealed that CD4+CD25^{high} T cells in infiltrating metastatic melanoma as well as tumor-free LNs express the Foxp3 transcription factor, strongly suggesting that this population includes T_{reg}.

\textit{Infiltrating CD4^{+}CD25^{high} T cells suppress in vitro the proliferation and cytokine production of infiltrating CD4^{+}CD25^{-} as well as CD8^{+} T cells}

We next evaluated the proliferative capacities and the regulatory function of CD4^{+}CD25^{high} T cells from metastatic melanoma LNs. For this purpose, we sorted CD4^{+}CD25^{high} as well as CD4^{+}CD25^{-} and CD8^{+} T cells, and tested them in vitro proliferation assays. In all the nine metastatic LNs tested from six different patients, the sorted CD4^{+}CD25^{high} T cells proliferated poorly and did not produce IL-2 or IFN-\gamma in response to allogeneic stimulation (Figs. 3, A, D, and E), thus exhibiting an anergic profile similar to what has been described for human T_{reg} (24, 25, 27, 28, 30–33). In contrast, CD4^{+}CD25^{-} T cells proliferated vigorously and produced both IL-2 and IFN-\gamma in response to allogeneic stimulation (Fig. 3, A and D, and data not shown).

Importantly, the proliferation of CD4^{+}CD25^{-} T cells was strongly inhibited in a dose-dependent manner when cocultured with CD4^{+}CD25^{high} T cells (Fig. 3, A and B). The median percentage of inhibition at a 1:1 CD4^{+}CD25^{high}:CD4^{+}CD25^{-} T cell ratio obtained in nine metastatic LNs was 77.5\% (range 51–98\%) and remained detectable even at a 1:8 or 1:10 ratio in most of the
five cases where all ratios were tested (Fig. 3, A and B). In addition, CD4+/CD25high T cells strongly inhibited IL-2 and IFN-γ production of CD4+/CD25− T cells (Fig. 3D, and data not shown) corresponding to a 95.5 ± 6.6% of inhibition for IL-2 and 98.5 ± 3.8% for IFN-γ at a 1:1 ratio. It is noteworthy that at 1:8 or 1:10 ratios, which almost correspond to the ratios observed in metastatic LNs, the inhibition of cytokine production was still major (~90% inhibition; Fig. 3C, and data not shown), while the inhibition of proliferation was weaker (~30% inhibition; Fig. 3A). This suggests that infiltrating CD4+/CD25high T cells may be more suppressive on T cell functions than on T cell proliferation. In four metastatic LNs, the suppressive activity of CD4+/CD25high T cells was also tested at a 1:1 ratio against sorted infiltrating CD8+ T cells. Although these cells proliferated to a lower extent than CD4+/CD25− T cells in response to allogeneic stimulation, their proliferation was also strongly inhibited by CD4+/CD25high T cells in a dose-dependent manner with a median percentage of inhibition of 62% at a 1:1 ratio (Fig. 3B, and data not shown). Similarly, the IFN-γ production of CD8+ T cells was also strongly inhibited by CD4+/CD25high T cells (Fig. 3E), with a median percentage of inhibition of 85% at a 1:1 ratio. In two LNs with minimal tumor invasion, the inhibition of proliferation of both CD4+/CD25− and CD8+ T cells was weak, around 50% at 1:1 ratio (data not shown). In addition, as expected from recent studies on murine LNs (46), CD4+/CD25high T cells isolated from four tumor-free LNs from three different patients also displayed some suppressive activity, albeit not as potent as in metastatic LNs, because suppression was not detected at a lower ratio than 1:2 or 1:4 (Fig. 3C).

Taken together, CD4+/CD25high T cells infiltrating melanoma metastatic LNs, and to a lesser extent tumor-free LNs, suppressed in vitro the proliferation and cytokine production of both infiltrating CD4+/CD25− as well as CD8+ T cells.

**Suppression by tumor-infiltrating CD4+/CD25high T cells is mediated through a cell contact mechanism**

Although controversial, the mechanism of action of human CD4+/CD25high Treg appears to be largely cell contact dependent (24, 25, 27, 28, 30–33). The role of cytokines, like IL-10 or TGF-β, as well as cell surface molecules, like CTLA-4 or GITR, is still a matter of debate (14). Therefore, we investigated whether infiltrating CD4+/CD25high T cells inhibited cell proliferation in vitro through a cell-contact- and/or cytokine-dependent mechanism. Transwell experiments performed in four metastatic LNs revealed that CD4+/CD25high T cells required cell contact to suppress proliferation of CD4+/CD25− T cells, because in all cases the inhibition of proliferation was either completely or partially abolished by the transwell (Fig. 4A, and data not shown). Preincubation of CD4+/CD25high T cells with blocking anti-IL-10 or anti-TGF-β1,3 Abs significantly reverted the suppression in experiments performed in three cases, while isotype control blocking mAbs did not (Fig. 4A, and data not shown). As control, the preincubation of CD4+/CD25− T cells alone with these blocking Abs did not affect their proliferation (data not shown). Thus, the suppressive activity of LN-infiltrating CD4+/CD25high T cells was found to be both contact and cytokine dependent. Interestingly, we found that preincubation of infiltrating CD4+/CD25high T cells with blocking anti-CTLA-4 Ab also significantly reverted the suppression (Fig. 4A). In all the cases tested, the anti-GITR Ab did not significantly alter the suppressive activity of the CD4+/CD25high T cells (Fig. 4A). Finally and as previously described (27, 30–32), addition of IL-2 (50 or 100 IU/ml) allowed CD4+/CD25high T cells to proliferate and abolished their suppressive activity (data not shown).

Therefore, CD4+/CD25high T cells infiltrating metastatic LN suppress CD4+/CD25− T cells in a cell-contact- and CTLA-4-dependent mechanism. In addition, a cytokine-dependent mechanism could also be involved.

**Tumor-infiltrating CD4+/CD25high but also CD4+/CD25− T cells secrete IL-10 and/or TGF-β**

Because the suppressive activity of CD4+/CD25high T cells was abolished by anti-IL-10 or anti-TGF-β1,3 blocking Abs, we investigated whether infiltrating CD4+/CD25high and CD4+/CD25− T cells indeed produced these cytokines upon in vitro stimulation. We found that CD4+/CD25high T cells from metastatic LNs with large tumor invasion produced IL-10 upon allogeneic stimulation (36.6 up to 279.2 pg/ml; mean, 110.8 pg/ml), while in cases of minimal tumor invasion such a production was not detected (Fig. 4B). Because in these latter cases a lower level of inhibition of CD4+/CD25− T cell proliferation was also observed compared with more advanced disease, this suggests that IL-10 production may be correlated to the strength of suppression detected in vitro (Figs. 3B and 4B). However, stronger TCR-mediated stimulation using coated anti-CD3 and soluble anti-CD28 Abs revealed that these cells also displayed the capacity to secrete IL-10 (data not shown). In contrast, infiltrating CD4+/CD25− T cells also secrete IL-10 (27.9 up to 265.9 pg/ml; mean, 130 pg/ml) upon allogeneic stimulation, mostly in case of large tumor invasion (Fig. 4B). In tumor-free LNs, we similarly observed that both CD4+/CD25high and CD4+/CD25− T cells could produce IL-10, albeit at slightly lower levels (mean, 84 and 69 pg/ml, respectively).

In few cases, infiltrating CD4+/CD25high T cells and CD4+/CD25− T cells were found to produce TGF-β1 at a substantial level (>2000 and up to 8500 pg/ml) (Fig. 4C). In the case of minimal tumor invasion, such a TGF-β1 secretion was not observed and could not be induced by stimulation with anti-CD3 and anti-CD28 Abs (data not shown). Finally, TGF-β1 production was not detected when analyzing T cells from tumor-free LNs (data not shown).

The fact that infiltrating CD4+/CD25− T cells secreted IL-10 and/or TGF-β1 suggested that they may also display some suppressive activity. Indeed, when tested functionally in coculture experiments with infiltrating CD8+ T cells, irradiated CD4+/CD25−
T cells suppressed the proliferation and IFN-γ production of CD8+ T cells (data not shown).

Altogether, these data indicate that both infiltrating CD4+CD25high and CD4+CD25+ T cells can produce the immunosuppressive cytokines IL-10 and/or TGF-β, and that IL-10 may play a role in the suppressive activity of CD4+CD25high T cells. They also provide evidence that cells with a Tr1/Th3-like phenotype (22, 23) are also present in melanoma metastatic LNs, mostly in cases of large tumor invasion. Finally, because both infiltrating CD4+CD25high and CD4+CD25+ T cells did not produce IL-4 upon stimulation (data not shown), the presence of Th2 cells is unlikely.

**Tumor-infiltrating CD4+CD25high T cells display a large polyclonal TCR Vβ (TCRBV) repertoire**

It has been largely described in mice and humans that oligoclonality of TCR usage and characteristic features of complementarity-determining regions 3 (CDR3) regions may reveal Ag-expanded T cells in a given T lymphocyte population even if the Ag is not known (47). Thus, to obtain insight into the potential Ag-driven expansion of CD4+CD25high T cells infiltrating melanoma metastatic LNs, we performed a detailed Immunoscope analysis of their TCRBV repertoire by, first, quantifying the BV family usage through real-time PCR, and, second, by determining their CDR3 chain length distributions through Immunoscope analysis (42, 43). We found that both CD4+CD25high and CD4+CD25+ T cell populations from three metastatic LNs from different patients and from one tumor-free LN expressed an highly diverse set of BV families and that these populations differed quantitatively only on a limited number of BV families for a given patient. Similar results were obtained for the four LNs studied and a representative case is shown in Fig. 5A. In each case, including the tumor-free LN, similar BV families (as BV15, 20, or 23, for example) were poorly or not detected in both CD4+CD25high and CD4+CD25+ T cell populations. They correspond to infrequently used BV families in the
no evidence for oligoclonal expansion even in case of differential usage of a given BV (see for example the BV2 profile among the representative BV profiles shown in Fig. 5B).

Overall, these data do not argue for a restricted Ag-driven expansion of CD4+/CD25high T cells infiltrating melanoma metastatic LNs.

**Discussion**

CD4+/CD25high Treg have been shown in murine models to play an important role in dominant peripheral tolerance by controlling potentially harmful autoreactive T cells. They have been also implicated recently in the down-regulation of antitumor responses in transplantable murine tumor models (15–17). Such a role could explain the poor clinical efficiency of immunotherapeutic protocols in human tumors. Recently, it was shown that CD4+CD25high Treg specifically express a transcription factor, Foxp3, which plays a major role in their development and function (18–21, 26, 29). Foxp3 is currently considered to be the most accurate marker to identify Treg (21). Indeed, in human PBMCs, we found that Foxp3 was expressed almost exclusively by the CD4+CD25high T cell population that is known to contain Treg (27, 28, 30, 31). In the present study of melanoma metastatic LNs, we identified substantial Foxp3 expression among infiltrating CD4+CD25high T lymphocytes in all the cases studied. Furthermore, such infiltrating CD4+CD25high T cells display the phenotype of peripheral memory T cells (CD45RO+CD27+) (44) and constitutively express high levels of CD152 (CTLA-4). Functionally, CD4+CD25high T cells do not proliferate in vitro and do not produce IL-2 or IFN-γ upon TCR-mediated activation. They clearly suppress both the proliferation and cytokine production of infiltrating CD4+CD25− as well as CD8+ T cells in a cell-contact-dependent manner. All these features described above have been recently ascribed to human peripheral Treg (24, 25, 27, 28, 30–33). The fact that these cells widely inhibit both infiltrating CD4+CD25+ as well as CD8+ T cells is in accordance with the observation that once activated, both mice and human Treg suppress other T cells in an Ag-independent manner (13, 14). Thus, our data reveal that CD4+CD25high T cells found in melanoma metastatic LNs behave as Treg, suggesting that they may play an active role in downregulating local antitumor responses. Such a role for suppressive T cells has been suggested long time ago in melanoma by Mukherji and colleagues (48, 49), who observed CD4+ T cell clones with some suppressive activity from metastatic LNs. We have preliminary evidence that these infiltrating CD4+CD25high T cells could inhibit in vitro the proliferation of a CD8+ T cell clone recognizing the tumor Ag MelanA/Mart-1. However, as mentioned above, such an observation is not surprising due to the suppressive activity of Treg independent of the specificity of the target effectors (13, 14).

Importantly, we found that such CD4+CD25high Treg are over-represented in metastatic LNs and express high levels of CTLA-4, CD69, and CD27, consistent with the phenotype of activated Treg. This directly raises the question whether these cells are recruited and expanded at the tumor site from circulating Treg or from resident LN Treg. It was recently demonstrated by Fisson et al. (46) that in mice, a fraction of Treg present in normal LNs and spleen is continuously activated and is dividing in the steady-state while another fraction remains quiescent. In addition, according to what was suspected (14), Salomon’s group have nicely shown that activation of LN Treg is driven by physiological sustained presentation of tissue self-Ags in draining LNs (46). In our case, we found the presence of activated Treg in metastatic LNs, but also in tumor-free satellite LNs, as well as in two cutaneous draining LNs from healthy donors. In the cases of tumor-free and normal LNs, the

---

**FIGURE 4.** Cell-contact- and cytokine-dependent suppression activity of infiltrating CD4+CD25high T cells could be identified. A, [3H]Thymidine incorporation of infiltrating CD4+CD25high and CD4+CD25− T cells is shown for a representative metastatic LN under allogeneic stimulation at a 1:1 ratio separated or not by a transwell (TW) or in the presence of blocking Abs: anti-TGF-β1 (αTGFβ1), anti-IL-10 (αIL-10), anti-CTLA-4 (αCTLA-4), or anti-GITR (αGITR). Suppressive activity of infiltrating CD4+CD25high T cells is indicated above each tumor name in B.

---

normal human TCR repertoire (42). When looking at the CDR3β chain length profiles (Fig. 5B), both populations showed an almost Gaussian-like curve distribution for each BV family studied with

---

**FIGURE 4.**
observed activated Treg could well correspond to such Treg activated at the steady-state because they express Foxp3 (data not shown). In the case of metastatic LNs, the observed expansion of the Treg already present locally may be due to an increased Ag stimulation either by tumor-specific Ags or self-Ags expressed by tumor cells. In accordance with this hypothesis, the fact that CD4⁺CD25high T cells in both metastatic and tumor-free LNs express a largely polyclonal repertoire does not argue for a stimulation by a limited number of Ags, but rather for a stimulation by a large panel of Ags. However, we cannot exclude that such an expansion is due to nonspecific stimulation of steady-state Treg in the context of a local suppressive microenvironment generated by invading tumor cells via immunosuppressive cytokines (as TGF-β or IL-10). To solve these issues of the Ag specificities of the Treg expanded at the tumor site, further studies analyzing isolated infiltrating Treg clones are needed. In favor of an Ag-driven stimulation of infiltrating Treg, Wang’s group (50) recently identified the tumor Ag LAGE-1 as the ligand recognized by some Treg infiltrating melanoma, Wang’s group (50) recently identified the tumor Ag LAGE-1 as the ligand recognized by some Treg infiltrating melanoma, and also CD4⁺CD25high T cells (data not shown), this suggests that the anti-TGF-β1,3 Abs could revert this inhibition indicating that part of the mechanism may also be cytokine-dependent. However, the drastic effect of anti-TGF-β1,3 Abs contrasts with the fact that CD4⁺CD25high T cells were rarely found to secrete TGF-β1, the only TGF-β isoform detected by our ELISA. Because real-time PCR analysis did not allow us to detect any expression of either TGF-β2 or TGF-β3 isoforms by CD4⁺CD25high T cells (data not shown), this suggests that the anti-TGF-β1,3 blocking Ab may exert its effect through cell surface-bound TGF-β1, which was recently implicated in the mediation of cell-contact-dependent immunosuppression by CD4⁺CD25high T cells (52). It is of course difficult to extrapolate in vivo the mechanisms of suppression suggested by in vitro experiments. This is well illustrated in the mice model were the mode of action of Treg in vivo remains unclear and is still largely debated (14). To explain the in vivo suppressive activity of Treg, at low CD4⁺CD25high:CD4⁺CD25− ratio while needing direct cell contact, several groups (53–56) have shown that CD4⁺CD25high Treg may convey a suppressive activity to other CD4⁺ T cells that was found to be contact independent and either IL-10 (55) or TGF-β dependent (56), a phenomenon known as infectious tolerance (57). Thus, it is possible that the cytokine-dependent suppressive activity observed in our study may reflect the detection of ongoing not yet fully inhibited antitumor immune response should be easier to isolate for further immunotherapeutic approaches (3).

Tumor-infiltrating Foxp3⁺CD4⁺CD25high Treg were found, as expected, to operate in vitro through a cell contact mechanism. However, the degree of inhibition observed was almost correlated to the secretion of IL-10 by CD4⁺CD25high and also CD4⁺CD25− T cells in our in vitro assay. In addition, anti-IL-10 or anti-TGF-β1,3 Abs could revert this inhibition indicating that part of the mechanism may also be cytokine-dependent. However, the drastic effect of anti-TGF-β1,3 Abs contrasts with the fact that CD4⁺CD25high T cells were rarely found to secrete TGF-β1, the only TGF-β isoform detected by our ELISA. Because real-time PCR analysis did not allow us to detect any expression of either TGF-β2 or TGF-β3 isoforms by CD4⁺CD25high T cells (data not shown), this suggests that the anti-TGF-β1,3 blocking Ab may exert its effect through cell surface-bound TGF-β1, which was recently implicated in the mediation of cell-contact-dependent immunosuppression by CD4⁺CD25high T cells (52). It is of course difficult to extrapolate in vivo the mechanisms of suppression suggested by in vitro experiments. This is well illustrated in the mice model were the mode of action of Treg in vivo remains unclear and is still largely debated (14). To explain the in vivo suppressive activity of Treg, at low CD4⁺CD25high:CD4⁺CD25− ratio while needing direct cell contact, several groups (53–56) have shown that CD4⁺CD25high Treg may convey a suppressive activity to other CD4⁺ T cells that was found to be contact independent and either IL-10 (55) or TGF-β dependent (56), a phenomenon known as infectious tolerance (57). Thus, it is possible that the cytokine-dependent suppressive activity observed in our study may reflect...
the presence of such de novo-generated suppressive T cells. In contrast, it has been well documented that Treg with cytokine-dependent suppressive activity could be induced from mature CD4+ T cells under defined conditions of Ag stimulation in the presence of immunosuppressive drugs or cytokines (28, 58, 59). Our data suggest that Tr1/Th3-like T cells (22, 23) secreting both IL-10 and TGF-β could be detected in melanoma metastatic LNs among CD4+CD25− T cells. Because melanoma cells have been described to secrete either IL-10 (60) or TGF-β (61), it is possible that the tumor cells themselves participate locally to the induction of such CD4+CD25− suppressor T cells. In addition, it is noteworthy that TGF-β has been shown to promote the expansion of CD4+CD25high Treg (62) and that blockade of TGF-β signaling has been recently implicated in the immune-mediated eradication of tumors (63). This suggests that melanoma cells could also use TGF-β secretion to induce the local expansion of Foxp3+CD4+CD25high Treg observed in our study. Taken together, the increased proportion of infiltrating Foxp3+CD4+CD25high Treg as well as the suppressive activity of infiltrating CD4+CD25− T cells support the idea that the local suppressive network is likely to be complex in metastatic melanoma and that distinct subtypes of suppressive T cells may be involved.

It has been recently shown in a murine model of Leishmania major infection that CD4+CD25high Treg control the persistence of the parasite by suppressing, through both IL-10-dependent and IL-10-independent mechanisms, the ability of CD4+CD25− effector T cells to eliminate the parasite (64). In addition, the maintenance of strong resistance to reinfection, known as concomitant immunity, is also controlled by such CD4+CD25high Treg, suggesting that the recirculating pool of memory cells is maintained while effector T cells are suppressed locally (65). This situation strikingly parallels some features of tumor immunology where concomitant immunity is a well-known phenomenon (65) and where local immunosuppression appears to be important (10). Further studies on melanoma patients are needed to determine whether infiltrating CD4+CD25high Treg, as in the L. major model, effectively suppress in vivo local effector immune responses. To this respect, immunotherapeutic strategies aimed to counteract in vivo the action of Treg might provide important answers to this hypothesis and would have crucial impacts on the designing of efficient vaccination protocols for the treatment of melanoma patients.

Acknowledgments

We thank A. Bandaier, A. Cumanu, J. Di Santo, D. Guy-Grand, and P. Vieira for comments and helpful discussions; A. Archimbaud, N. Basset-Seguin, and L. Ollivaud for providing us with melanoma-patient-derived tumor material; P. Desgranges for tissue samples; J. Treton for blood samples; the cytometry department of the Institut Pasteur (Paris, France) for MoFlo cell-sorting experiments; M. Lipp for CCR7 and CXCR5 Abs; A. Lim for Immunoscope analysis; and N. Fazilleau for helpful technical assistance. We also thank the patients and blood donors for their consent in participating in this study.

References